UROGEN PHARMA LTD Share Price Today: Live Updates & Key Insights

UROGEN PHARMA LTD share price today is $17.96, up -5.22%. The stock opened at $18.65 against the previous close of $18.59, with an intraday high of $18.775 and low of $17.5.

UROGEN PHARMA LTD Share Price Chart

UROGEN PHARMA LTD

us-stock
To Invest in {{usstockname}}
us-stock

UROGEN PHARMA LTD Share Price Performance

$17.96 -0.0522(-5.22%) URGN at 23 Mar 2026 03:39 PM Biotechnology
Lowest Today 17.5
Highest Today 18.775
Today’s Open 18.65
Prev. Close 18.59
52 Week High 30.00
52 Week Low 3.42
Day’s Range: Low 17.5 High 18.775
52-Week Range: Low 3.42 High 30.00
1 day return -
1 Week return -5.82
1 month return -15.9
3 month return -25.19
6 month return -2.05
1 year return +47.85
3 year return +123.76
5 year return -10.88
10 year return -

UROGEN PHARMA LTD Institutional Holdings

RTW INVESTMENTS, LLC 9.33

Paradigm Biocapital Advisors LP 9.19

The Toronto-Dominion Bank 6.55

BlackRock Inc 5.30

Morgan Stanley - Brokerage Accounts 5.19

Jefferies Financial Group Inc 4.52

SILVERARC CAPITAL MANAGEMENT, LLC 3.57

American Century Companies Inc 2.79

RTW Biotech Opportunities Ord 2.79

SG Americas Securities, LLC 2.38

MENORA MIVTACHIM HOLDINGS LIMITED 2.37

HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 2.31

JPMorgan Chase & Co 2.20

TANG CAPITAL MANAGEMENT LLC 2.05

D. E. Shaw & Co LP 1.98

iShares Russell 2000 ETF 1.85

Orbimed Advisors, LLC 1.80

State Street Corp 1.68

Frontier Capital Management CO Inc 1.61

Migdal Insurance & Financial Holdings Ltd 1.58

Citadel Advisors Llc 1.52

TCG Crossover Management, LLC 1.47

American Century Small Cap Growth Inv 1.34

American Century U.S. Small Cap Growth 1.34

Biotech Growth Ord 1.20

Fidelity Small Cap Index 0.74

Xtrackers S&P 500 Swap ETF 1C 0.69

T. Rowe Price Health Sciences 0.61

iShares Biotechnology ETF 0.60

State St Russell Sm/Mid Cp® Indx SL Cl I 0.54

iShares Russell 2000 Growth ETF 0.52

MEDICAL BioHealth EUR Acc 0.43

State Street® SPDR® Ptf Dev Wld exUS ETF 0.37

Vanguard Russell 2000 ETF 0.36

State St Russell Sm Cap® Indx SL Cl I 0.25

Vanguard Health Care ETF 0.24

Fidelity Enhanced Small Cap ETF 0.24

ARK Israel Innovative Technology ETF 0.24

TM Brunel Smaller Companies Eqs A Acc 0.23

iShares Micro-Cap ETF 0.20

UROGEN PHARMA LTD Market Status

Strong Buy: 5

Buy: 1

Hold: 2

Sell: 0

Strong Sell: 0

UROGEN PHARMA LTD Fundamentals

Market Cap 857.78 M

PB Ratio 19.2691

PE Ratio 0.0

Enterprise Value 866.63 M

Total Assets 200.46 M

Volume 975333

UROGEN PHARMA LTD Company Financials

Annual Revenue FY23:77275000 77.3M, FY22:64357000 64.4M, FY21:48042000 48.0M, FY20:11799000 11.8M, FY19:18000 0.0M

Annual Profit FY23:67937000 67.9M, FY22:56703000 56.7M, FY21:42885000 42.9M, FY20:10790000 10.8M, FY19:18000 0.0M

Annual Net worth FY23:-105097000 -105.1M, FY22:-109163000 -109.2M, FY21:-110820000 -110.8M, FY20:-128484000 -128.5M, FY19:-100530000 -100.5M

Quarterly Revenue Q3/2025:27482000 27.5M, Q2/2025:24215000 24.2M, Q1/2025:20254000 20.3M, Q3/2024:25204000 25.2M, Q2/2024:21848000 21.8M

Quarterly Profit Q3/2025:24204000 24.2M, Q2/2025:20665000 20.7M, Q1/2025:17924000 17.9M, Q3/2024:22751000 22.8M, Q2/2024:19619000 19.6M

Quarterly Net worth Q3/2025:-33347000 -33.3M, Q2/2025:-49940000 -49.9M, Q1/2025:-43843000 -43.8M, Q3/2024:-23673000 -23.7M, Q2/2024:-33403000 -33.4M

About UROGEN PHARMA LTD & investment objective

Company Information UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Organisation Biotechnology

Employees 291

Industry Biotechnology

CEO Ms. Elizabeth A. Barrett

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

UROGEN PHARMA LTD FAQs

What is the share price of UROGEN PHARMA LTD today?

The current share price of UROGEN PHARMA LTD is $17.96.

Can I buy UROGEN PHARMA LTD shares in India?

Yes, Indian investors can buy UROGEN PHARMA LTD shares by opening an international trading and demat account with Motilal Oswal.

How to buy UROGEN PHARMA LTD shares in India?

You can easily invest in UROGEN PHARMA LTD shares from India by:

Can I buy fractional shares of UROGEN PHARMA LTD?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of UROGEN PHARMA LTD?

UROGEN PHARMA LTD has a market cap of $857.78 M.

In which sector does UROGEN PHARMA LTD belong?

UROGEN PHARMA LTD operates in the Biotechnology sector.

What documents are required to invest in UROGEN PHARMA LTD stocks?

To invest, you typically need:

What is the PE and PB ratio of UROGEN PHARMA LTD?

The PE ratio of UROGEN PHARMA LTD is N/A and the PB ratio is 19.27.